Your responses are somewhat confusing to me. As

New Post Public Reply Private Reply Replies (1) Message Board
blafarm chessmaster #53413
857
Your responses are somewhat confusing to me.

As mentioned, I am always happy to be corrected, that's how I learn and grow, but let's take a moment and unpack your responses.

You Wrote:
Quote:
This statement is FALSE without clarification ...

The clock is absolutely not reset toward the PDUFA date because they have a rolling review. Now if you mean reset with respect to them responding for a PDUFA date I will give you that

My Response:
I don't understand the distinction you are making. How does a "clock not reset toward the PDUFA date" -- differ from a clock "reset with respect to them responding for a PDUFA date"?

Did you take the time to read the "FDA: CDER 21st Century Review Process" document that I clearly linked in my post?

https://www.fda.gov/media/78941/download

Allow me to provide you with an excerpt from page 20:
Quote:
A refusal-to-file decision ends the review process. The applicant’s options are to resubmit the NDA/BLA with the deficiencies addressed (the resubmission is considered an original new application) or to request that the NDA/BLA be filed over protest. PDUFA V “Program” applications that are subsequently filed over protest are removed from “The Program” and become subject to the standard 6- or 10-month review clock, as applicable.
Please provide clarification.

You Wrote:
Quote:
Now wouldnt this be a HUGE question to ask on the conference call? I hope someone reads this and asks.

My Response:
If my statement is "absolutely" "FALSE" as you contend, then why does this question need to be asked? You obviously already know the answer, and if you don't, why don't you simply ask the question yourself during the call?

You Wrote:
Quote:
This frustrates me that so many are uninformed. The only way to clear this up is to ask the question on the conference call. What impact has the RTF had on the PDUFA date? Will the clock reset to another 6 months.

My Response:
You seem to be saying that you don't know the answer either -- as you want the company to clear up this question on the conference call. So then, you and I are maybe both "uninformed".

You Wrote:
Quote:
They will have to say it could but it wont because 2/3rds of the Rolling review are theoretically going on right now so when they get the last submission they have very little left to review. We are weeks to months away from THE PDUFA date. It will likely be this year but I honestly dont think that we will ever find out because I expect drug approval before then and then HIV can be the label extension.

My Response:
I don't know quite how to process this. You seem to be saying that the company will have to "say it", but regardless of what the company says, the clock "wont [be reset] because 2/3rds of the Rolling review are theoretically going on right now so when they get the last submission they have very little left to review."

I think you'd have to agree, there's quite a bit of tension in that statement. You seem to be asserting that it doesn't make a difference what the company says -- the clock will abide by your own understanding of how the universe works.

You Wrote:
Quote:
We are weeks to months away from THE PDUFA date. It will likely be this year but I honestly dont think that we will ever find out because I expect drug approval before then and then HIV can be the label extension.

My Response:
Since you contend my statement is "absolutely" "FALSE", which is it, are we weeks away or months away? I'm assuming you know the answer to this question.

Also, do you really believe: "I honestly dont think that we will ever find out"? In other words, do you really believe we will never learn this information?


Final Thoughts:
I began my post with this sentence:

"Happy to be corrected, but here is my understanding of the process."

I tend to chose my words carefully, so you can believe me when I said that I was "happy to be corrected".

Like many government agencies, the FDA's regulatory documents can be vague and confusing for laypersons to interpret and comprehend. I've invested time reading more documents than I care to remember in an effort to understand the moving parts of this process -- but I'm not perfect.

I may have possibly included an incorrect data point in my post. And I previewed this very real possibility when I wrote that I would be "happy to be corrected".

I have nothing against you, and I would be happy to be corrected by you. However, your responses don't exactly instill confidence that you know any more than I do.

And if that's the case, you might consider not accusing someone of making an "absolutely" "FALSE" statement unless you can clearly articulate the correct answer.

Again, I am happy to corrected as we all want to know the answer to this question.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading

Top 5 Most Recently Viewed Articles

DoorLoop Achieves Prestigious Award for User Satisfaction

Updated Category News Views 227

DoorLoop Achieves Notable Recognition in Property Management Software Celebrated on Capterra's 2025 Shortlist with Outstanding Satisfaction Ratings DoorLoop, the innovative property management software designed for efficiency, has received the honor of being the highest-rated choice among property management software in the latest Capterra selection. This recognition from...

Continue Reading
The Surprising Rise of Robocalls: What We Can Do About It

Updated Category News Views 530

The Robocall Epidemic of 2025 In a startling revelation, U.S. consumers experienced over 4.3 billion robocalls just in July 2025. This staggering statistic, reported by YouMail's Robocall Index, shines a light on the growing nuisance that has plagued phone users for years. Interestingly, while July's figures remained consistent with the previous year, there has been a...

Continue Reading
Revolutionizing Telecommunications: The Launch of 5-Band RRU

Updated Category News Views 197

ZTE and MTN’s Groundbreaking Collaboration for Telecom Innovation ZTE Corporation and MTN have announced the successful commercial deployment of an innovative technology—the world's first 5-band Remote Radio Unit (RRU). This significant achievement highlights a new era in telecommunications, with implications that stretch beyond individual companies to impact the...

Continue Reading
Innovative Hydro Project Set to Transform Energy Landscape

Updated Category News Views 167

Introducing a Revolutionary Hydroelectric Project In a significant move towards advancing renewable energy, Current Hydro has announced the launch of its 28.5 MW Robert C. Byrd Locks and Dam Hydroelectric Project. This project will utilize the flows of the Ohio River, providing reliable and sustainable energy solutions while also focusing on environmental preservation and...

Continue Reading
Mercury Systems Secures Defense Contract to Enhance RF Solutions

Updated Category News Views 213

Mercury Systems Wins Key Defense Contract Mercury Systems, Inc. (NASDAQ: MRCY) is making headlines as it has been selected by the U.S. Department of Defense (DoD) for an important contract that seeks to bolster America’s defense supply chain. The focus centers around the development of a state-of-the-art RF signal conditioning multi-chip package (MCP), which is pivotal...

Continue Reading